Dyne Therapeutics joined PPMD for a community webinar on April 12, 2023 to discuss Dyne’s FORCE™ platform. Ashish Dugar, PhD, MBA, Dyne’s Chief Medical Affairs Officer, and Molly White, Dyne’s Vice President, Global Head of Patient Advocacy and KOL Engagement, discussed Dyne’s DELIVER clinical trial, a Phase 1/2 study evaluating DYNE-251 for the treatment of individuals with Duchenne muscular dystrophy who have mutations amenable to exon 51 skipping.

If you missed the live event, the recording can be found below.

Watch the Recording